American Cancer Society. (2015, June 10). Breast Cancer. Retrieved from: http://www.cancer.org/cancer/breastcancer/index.
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, Barrios CH, et al. ESO-ESMO 2nd International Consesus Guidelines for advanced breast cancer (ABC2). (2014). The Breast. 23: 489-502.
Eisen A, Fletcher GG, Gandhi S, Mates M, Freedman OC, Dent SF, Trudeau ME and members of the Early Breast Cancer Systemic Therapy Consensus Panel. Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. (2015, March). Current Oncology. 22(S1): S67-S81.
Joy AA, Ghosh M, Fernandes R, Clemons MJ. Systemic treatment approaches in HER2-negative advanced breast cancer - guidance on the guidelines. (2015, March). Current Oncology. 22(S!): S29-S42.
Morrow M, Burstein HJ, and Harris JR. Malignant tumors of the breast. DeVita VT Jr, Lawrence TS, & Rosenberg SA. (2015). Cancer: Principles and Practice of Oncology. (10th Edition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 79: 1117-1156.
National Cancer Institute. (2015, July 8). Breast Cancer Treatment for Health Professionals (PDQ®).
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 2.2015). Retrieved from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline. (2014, October). Journal of Clinical Oncology. 32(29): 3307-3331.
Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. (2015, August). Journal of Clinical Oncology. 33(24): 2695-2706.×